Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
Details : Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiv...
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : $450.0 million
November 24, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
Details : The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s...
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : $450.0 million
November 10, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Analysis Supports GOCOVRI for Motor Complications for People With PD
Details : At week 12, participants treated with GOCOVRI reported statistically significant improvements in motor control for daily activities compared to placebo (least-squares mean changes from baseline of –3.4 points for GOCOVRI and –1.4 for placebo).
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia.
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adamas Announces FDA Filing Acceptance of sNDA to Modify Indication Statement for Gocovri
Details : Adamas has proposed to include GOCOVRI as an appropriate therapy for the treatment of OFF episodes in PD patients receiving levodopa. The clinical evidence supporting GOCOVRI’s effect on OFF time was demonstrated in two large pivotal Phase 3 trials.
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable